(Q36807494)

16 August 2017

1 reference

title

Inhibition of Akt pathways in the treatment of prostate cancer (English)

1 reference

16 August 2017

1 reference

Nelson EC

1

1 reference

16 August 2017

Evans CP

2

1 reference

16 August 2017

Mack PC

3

1 reference

16 August 2017

Devere-White RW

4

1 reference

16 August 2017

Lara PN Jr

5

1 reference

16 August 2017

language of work or name

1 reference

1 May 2007

1 reference

Prostate Cancer and Prostatic Diseases

16 August 2017

1 reference

16 August 2017

10

1 reference

16 August 2017

331-339

1 reference

16 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500974

16 August 2017

0 references

cites work

Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

The emerging role of the PI3-K-Akt pathway in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Modulation of Akt kinase activity by binding to Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Bortezomib as a potential treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Akt-regulated pathways in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Clinical implications of neuroendocrine differentiation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Blocking the PI3K/PKB pathway in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Mechanisms of cancer chemoprevention by soy isoflavone genistein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Molecular effects of the isoflavonoid genistein in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Transcription levels of invasion-related genes in prostate cancer cells are modified by inhibitors of tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Structure-based optimization of novel azepane derivatives as PKB inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

A Phase II Trial of Tricyclic Nucleoside Phosphate in Patients with Advanced Squamous Cell Carcinoma of the Cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGF-R2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

A phase II study of perifosine in androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

Proteomic profiling from human samples: the body fluid alternative

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

Detecting proteins separated by 2-D gel electrophoresis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500974

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500974

1 reference

16 August 2017

1 reference